Aging & Elder Health Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Aging & Elder Health Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Genetronics Biomedical Corp.
Pancreatic cancer clinical trial begins using MedPulser tumor ablation system
April 10th, 2005
Genetronics Biomedical Corp. (GEB), a late-stage developer of oncology and other therapies using electroporation to deliver drugs and nucleic acids, announced that it has initiated a phase I clinical trial to treat pancreatic cancer using its MedPulser Tumor Ablation System. The U.S. Food and Drug Administration (FDA) has granted Genetronics orphan designation for this indication. The primary endpoint of this FDA-approved study is to determine the safety profile of the MedPulser electroporation therapy in conjunction with intralesionally injected bleomycin for the treatment of unresectable or incurable locally advanced pancreatic cancer. The...
Source: Aging & Elder Health Week (2005-04-10)
|
